KITE Insider Trading
KITE | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at KITE provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2016-12-23 00:52 | 2016-12-20 | Tomasello Shawn | Officer - Chief Commercial Officer | SELL | $50.86 | 4,901 | $249,265 | 49,635 | -9.0% |
| 2016-12-23 00:51 | 2016-12-20 | Kim Helen Susan | Officer - EVP, Business Development | SELL | $50.86 | 936 | $47,605 | 8,064 | -10.4% |
| 2016-12-23 00:50 | 2016-12-20 | Chang David D | Officer - EVP, R&D, Chief Medical Off. | SELL | $50.86 | 1,788 | $90,938 | 25,123 | -6.6% |
| 2016-12-23 00:48 | 2016-12-20 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | SELL | $50.86 | 2,482 | $126,235 | 92,995 | -2.6% |
| 2016-12-23 00:47 | 2016-12-20 | Belldegrun Arie | Director, Officer - Chairman, President and CEO | SELL | $50.86 | 3,493 | $177,654 | 24,707 | -12.4% |
| 2016-12-06 03:03 | 2016-12-01 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $50.76 | 1,500 | $76,134 | 15,811 | 0.0% |
| 2016-11-30 01:02 | 2016-11-25 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | OPT+S | $50.40 | 10,000 | $504,015 | 95,477 | 0.0% |
| 2016-11-15 02:57 | 2016-11-10 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | OPT+S | $50.65 | 10,000 | $506,466 | 95,477 | 0.0% |
| 2016-11-15 02:55 | 2016-11-10 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $50.18 | 1,500 | $75,270 | 15,811 | 0.0% |
| 2016-10-06 02:44 | 2016-10-03 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $54.81 | 1,500 | $82,214 | 15,811 | 0.0% |
| 2016-09-29 00:03 | 2016-09-26 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | OPT+S | $54.13 | 10,000 | $541,300 | 95,477 | 0.0% |
| 2016-09-03 01:34 | 2016-09-01 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $58.24 | 1,500 | $87,362 | 15,811 | 0.0% |
| 2016-08-27 01:38 | 2016-08-25 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | OPT+S | $58.28 | 10,000 | $582,775 | 95,477 | 0.0% |
| 2016-08-17 03:16 | 2016-08-12 | Kim Helen Susan | Officer - EVP, Business Development | OPT+S | $60.27 | 35,900 | $2,163,826 | 9,000 | 0.0% |
| 2016-08-03 01:51 | 2016-08-01 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $56.90 | 1,500 | $85,343 | 14,867 | 0.0% |
| 2016-07-27 02:03 | 2016-07-25 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | OPT+S | $50.94 | 10,000 | $509,350 | 95,401 | 0.0% |
| 2016-07-06 01:27 | 2016-07-01 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $50.00 | 1,500 | $75,007 | 14,867 | 0.0% |
| 2016-06-28 02:08 | 2016-06-23 | BUTITTA CYNTHIA M | Officer - Chief Operating Officer | OPT+S | $50.71 | 20,000 | $1,014,238 | 95,401 | 0.0% |
| 2016-06-09 02:27 | 2016-06-06 | DOUMANI ROY | Director | SELL | $58.04 | 14,000 | $812,581 | 27,865 | -33.4% |
| 2016-06-03 00:15 | 2016-05-31 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $50.65 | 3,000 | $151,949 | 14,867 | 0.0% |
| 2016-04-07 02:06 | 2016-04-04 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $50.00 | 10,000 | $500,000 | 95,401 | 0.0% |
| 2016-03-18 04:15 | 2016-03-15 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $44.88 | 9,000 | $403,943 | 14,867 | 0.0% |
| 2016-03-18 04:15 | 2016-03-15 | Sproule Rizwana F | Officer - VP Regulatory Affairs | OPT+S | $45.27 | 8,500 | $384,791 | 10,211 | 0.0% |
| 2016-03-18 04:14 | 2016-03-15 | Roberts Margo R | Officer - Chief Scientific Officer | OPT+S | $45.23 | 8,506 | $384,766 | 10,655 | 0.0% |
| 2016-03-04 03:13 | 2016-03-01 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $50.03 | 10,000 | $500,300 | 95,401 | 0.0% |
| 2016-02-20 00:14 | 2016-02-17 | Roberts Margo R | Officer - Chief Scientific Officer | OPT+S | $45.06 | 9,632 | $434,018 | 9,098 | 0.0% |
| 2016-02-20 00:13 | 2016-02-17 | Sproule Rizwana F | Officer - VP Regulatory Affairs | OPT+S | $45.08 | 9,567 | $431,278 | 8,741 | 0.0% |
| 2016-02-19 04:34 | 2016-02-16 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $44.07 | 9,000 | $396,653 | 13,742 | 0.0% |
| 2016-02-17 03:05 | 2016-02-12 | Roberts Margo R | Officer - Chief Scientific Officer | OPT+S | $64.16 | 18,750 | $1,202,964 | 9,098 | 0.0% |
| 2016-02-05 05:06 | 2016-02-02 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $50.13 | 1,900 | $95,247 | 94,007 | 0.0% |
| 2016-02-04 03:04 | 2016-02-01 | Better Marc | Officer - VP, Product Sciences | OPT+S | $47.34 | 9,000 | $426,037 | 7,688 | 0.0% |
| 2016-01-30 02:15 | 2016-01-27 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $51.62 | 8,100 | $418,128 | 94,007 | 0.0% |
| 2016-01-20 04:24 | 2016-01-15 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $55.26 | 9,000 | $497,379 | 13,742 | 0.0% |
| 2016-01-20 04:23 | 2016-01-15 | Sproule Rizwana F | Officer - VP Regulatory Affairs | OPT+S | $55.49 | 9,567 | $530,831 | 8,741 | 0.0% |
| 2016-01-20 04:22 | 2016-01-15 | Roberts Margo R | Officer - Chief Scientific Officer | OPT+S | $55.22 | 6,145 | $339,323 | 9,098 | 0.0% |
| 2016-01-06 03:45 | 2016-01-04 | Better Marc | Officer - VP, Product Sciences | OPT+S | $61.53 | 9,000 | $553,788 | 7,688 | 0.0% |
| 2015-12-30 03:17 | 2015-12-28 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $61.56 | 10,000 | $615,599 | 94,007 | 0.0% |
| 2015-12-18 03:33 | 2015-12-15 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $63.78 | 9,000 | $573,989 | 6,342 | 0.0% |
| 2015-12-18 03:33 | 2015-12-15 | Roberts Margo R | Officer - Chief Scientific Officer | OPT+S | $63.76 | 6,145 | $391,814 | 2,198 | 0.0% |
| 2015-12-18 03:32 | 2015-12-15 | Sproule Rizwana F | Officer - VP Regulatory Affairs | OPT+S | $63.76 | 9,567 | $609,994 | 2,941 | 0.0% |
| 2015-12-04 02:53 | 2015-12-01 | Better Marc | Officer - VP, Product Sciences | OPT+S | $76.31 | 9,000 | $686,819 | 1,888 | 0.0% |
| 2015-12-01 04:23 | 2015-11-27 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $86.45 | 15,000 | $1,296,680 | 75,507 | 0.0% |
| 2015-11-19 03:32 | 2015-11-16 | Roberts Margo R | Officer - Chief Scientific Officer | OPT+S | $78.16 | 6,145 | $480,270 | 2,198 | 0.0% |
| 2015-11-19 03:31 | 2015-11-16 | Wiezorek Jeffrey | Officer - SVP Clinical Development | OPT+S | $78.08 | 9,000 | $702,680 | 6,342 | 0.0% |
| 2015-11-19 03:29 | 2015-11-16 | Sproule Rizwana F | Officer - VP Regulatory Affairs | OPT+S | $78.13 | 9,567 | $747,507 | 2,941 | 0.0% |
| 2015-11-13 02:33 | 2015-11-10 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $80.00 | 5,000 | $400,000 | 75,507 | 0.0% |
| 2015-11-13 02:32 | 2015-11-10 | Chang David D | Officer - EVP, R&D, Chief Medical Off. | OPT+S | $80.02 | 30,800 | $2,464,616 | 6,904 | 0.0% |
| 2015-11-05 03:06 | 2015-11-02 | Better Marc | Officer - VP, Product Sciences | OPT+S | $71.07 | 9,000 | $639,652 | 1,888 | 0.0% |
| 2015-11-05 03:05 | 2015-11-02 | Chang David D | Officer - EVP, R&D, Chief Medical Off. | OPT+S | $71.08 | 7,700 | $547,292 | 6,904 | 0.0% |
| 2015-10-29 02:17 | 2015-10-27 | BUTITTA CYNTHIA M | Officer - COO and CFO | OPT+S | $69.91 | 10,000 | $699,120 | 75,507 | 0.0% |
How to Interpret $KITE Trades
Not every insider transaction in KITE is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $KITE shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for KITE
Insider activity data for KITE is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $KITE, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.